Aurinia Pharmaceuticals : Corporate Presentation (744a16d2 Aurinia Corporate Presentation May 2026)

Published: 2026-05-07 08:37:17 ET AUPH

Published on 05/07/2026 at 08:37 am EDT

Corporate Presentation

May 2026

Changing the Trajectory of Autoimmune Diseases

Continue LUPKYNIS commercial growth

Advance aritinercept development

mmercialization

diagnosis and

Recent Financial Results

Results for the Three Months Ended March 31

Three Months Ended March 31

% Change

2026

2025

Total Revenue

$77.7 million

$62.5 million

24%

Net Product Sales

$73.6 million

$60.0 million

23%

Net Income

$34.4 million

$23.3 million

48%

Diluted Earnings per Share

$0.25

$0.16

56%

Cash Flows from Operating Activities

$32.6 million

$1.3 million

2408%

® 5

2026 Financial Guidance

Guidance Range a

Total Revenue

$315 million to $325 million (up 11% to 15%)

Net Product Sales

$305 million to $315 million (up 12% to 16%)

Net Product Sales

$271.3M

$216.2M

$158.5M

$103.5M

$45.5M

$315.0M

$305.0M

2021 2022 2023 2024 2025

2026

Guidance Range a

a Guidance as of May 7, 2026 6

LUPKYNIS®

A calcineurin inhibitor (CNI) indicated in combination with a background immunosuppressive regimen for the treatment of adult patients with active

lupus nephritis

The first oral therapy approved for the treatment of

lupus nephritis

Lupus Nephritis (LN) Is Among the Most Severe and Dangerous Complications of Systemic Lupus Erythematosus (SLE)

SLE, commonly known as lupus, is a chronic autoimmune disease where the body's immune system mistakenly attacks its own healthy tissues and organs

Over 200,000 people in the United States are estimated to have SLE a, of which 20% to 60% develop LN b

Glomerulo-nephritis

LN occurs when the immune system attacks the kidneys

SLE/LN disproportionately affects women and people of color a

Measuring proteinuria (protein in the urine) is critical for monitoring disease activity and response to therapy c

Inflammation leads to blood and protein in the urine, impaired kidney function and even kidney failure

a U.S. Centers for Disease Control and Prevention 2024

® b KDIGO Lupus Nephritis Work Group, Kidney Int 2024 8

c Tamirou et al., Ann Rheum Dis 2016

Proteinuria Reduction Is Associated with Long-Term Renal Preservation

The larger the initial reduction in proteinuria in the first several months of management, the lower the risk of ESKD

ESKD=end-stage kidney disease

a Adapted with permission from Chen et al., Clin J Am Soc Nephro 2008

b Retrospective analysis of patients (N=86) enrolled in the prospective, controlled study of plasmapheresis in severe LN to determine long-term prognosis of achieving partial response. Complete

® response was defined as SCr ≤1.4 mg/dL and proteinuria ≤0.33 g/day within 5 years of study entry, and partial response was defined as ≤25% increase in baseline SCr and ≥50% reduction in baseline proteinuria to ≤1.5 g/day (but >0.33 g/day) within 5 years of entering the study. Kidney survival was determined by kidney failure (≥6 mg/dL SCr or the initiation of kidney replacement 9

therapy).

2024 American College of Rheumatology (ACR) Lupus Nephritis Treatment Guideline Update a

In November 2024, the ACR released an updated guideline for the treatment of LN that emphasizes early and aggressive treatment to preserve kidney function

Specifically, this updated guideline now details the following:

Goal is complete renal response, including reduction in proteinuria to

≤0.5 mg/mg within 6-12 months

Triple immunosuppressive

therapy, including a calcineurin inhibitor (CNI) or belimumab as first-line therapy

LUPKYNIS is the only CNI that

is FDA approved for LN

Reduce corticosteroid dose to minimize toxicity, with a

goal of ≤5 mg/day by 6 months

of therapy

® a 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis: Guideline Summary 2024 10

LUPKYNIS Is a Novel, Structurally Modified CNI that Targets LN with a Dual Mechanism of Action

T CELL CONTROL

Immune Modulation

DUAL MECHANISM

PODOCYTE SUPPORT

Kidney Filter Protection

Reduces T cell activation and cytokine release

Stabilizes podocyte structure and preserves the filtration barrier

Robust Clinical Study History

Randomized Phase 2 Study in 265 Patients

Improved Complete Renal Response Rate

Randomized Phase 3 Study in 357 Patients

Randomized Extension Study in 216 Patients

Established Safety Profile

Rapid Proteinuria Reduction

® 12

Significantly More Patients on LUPKYNIS Achieved a Complete Renal Response in AURORA 1 as Early as Week 24 a

Patients Achieving Complete Renal Response at Week 52, %

100

Patients Achieving Complete Renal Response at Week 24, %

100

40.8% (73/179)

22.5% (40/178)

(Primary Endpoint; p<0.001) b

81%

more likely

Patients treated with

LUPKYNIS were 81% more likely to achieve CRR at week 52 than those on MMF

+ corticosteroids alone

32.4% (58/179)

19.7% (35/178)

(Secondary Endpoint; p=0.002) b

64%

more likely

Patients treated with

LUPKYNIS were 64% more likely to achieve CRR at week 24 than those on MMF

+ corticosteroids alone

80 80

70 70

60 60

50 50

40 40

30 30

20 20

10 10

LUPKYNIS + MMF +

Corticosteroids

a Rovin et al., Lancet 2021

Placebo + MMF + Corticosteroids

LUPKYNIS + MMF +

Corticosteroids

Placebo + MMF + Corticosteroids

® b CRR was defined as urine protein-to-creatine ratio (UPCR) of ≤0.5 mg/mg, stable renal function (defined as eGFR ≥60 mL/min/1.73 m2 13

or no confirmed decrease from baseline in eGFR of >20%), no sustained corticosteroids and no administration of rescue medications

LUPKYNIS Rapidly Reduced Proteinuria in Fewer Days in AURORA 1 a

400

350

Days, median

300

250

200

150

100

63 days

29 days

fewer

days

Days, median

372 days

169 days

203

fewer

days

LUPKYNIS + MMF +

Corticosteroids (n=179)

Placebo + MMF + Corticosteroids (n=178)

LUPKYNIS + MMF +

Corticosteroids (n=179)

Placebo + MMF + Corticosteroids (n=178)

LUPKYNIS in combination with MMF and corticosteroids reduced proteinuria twice as fast as MMF and corticosteroids alone

® a Rovin et al., Lancet 2021

b Secondary endpoint

New Analysis Shows LUPKYNIS Associated with 53% Reduction in Risk of Renal-Related Event or Death

Time to Renal-Related Event or Death a

(AURORA 1 Phase 3 Population)

Treatment

Events (%)

HR (95% CI)

P-value

LUPKYNIS

26 (14.6)

0.466 (0.290, 0.747)

0.0012

Placebo

51 (28.7)

LUPKYNIS

Placebo

Censored

Probability of Event (%)

0 13 26 39 52 65

LUPKYNIS

0.0 [178]

3.4 [171]

10.2 [156]

13.7 [144]

14.9 [118]

14.9 [2]

Placebo

0.0 [178]

7.9 [161]

20.0 [137]

25.3 [125]

28.9 [92]

Probability [N at Risk]:

Time from First Dose (Weeks)

® a Time to renal-related event or death is defined as the time to the first occurrence of death, treatment failure, worsening proteinuria 15

or worsening eGFR

Adverse Reactions Occurring in ≥3% of Patients Treated with LUPKYNIS 23.7 mg Twice a Day and ≥2% Higher than Placebo in AURORA 1 and AURA-LV a

Adverse Reaction

LUPKYNIS 23.7 mg Twice a Day +

MMF + Corticosteroids (n=267)

Placebo +

MMF + Corticosteroids (n=266)

Glomerular Filtration Rate Decreased

26%

Hypertension

19%

Diarrhea

19%

13%

Headache

15%

Anemia

12%

Cough

11%

Urinary Tract Infection

10%

Abdominal Pain Upper

Dyspepsia

Alopecia

Renal Impairment

Abdominal Pain

Mouth Ulceration

Fatigue

Tremor

Acute Kidney Injury

Decreased Appetite

Further, in AURORA 2 b, LUPKYNIS demonstrated safety comparable to that seen in AURORA 1 with no unexpected safety signals observed through 3 years a,c

® a LUPKYNIS Prescribing Information 16

b AURORA 2 was a double-blind, placebo-controlled extension study of adults with active LN who completed AURORA 1

c Saxena et al., Arthritis Rheumatol 2024

Aritinercept

A dual BAFF/APRIL inhibitor for the potential treatment of autoimmune diseases

Aritinercept Is a Dual BAFF/APRIL Inhibitor

Aritinercept contains a BCMA-engineered extracellular binding domain optimized for superior affinity to BAFF and APRIL (others use TACI-engineered extracellular binding domain)

BCMA has a stronger natural affinity for APRIL than TACI a

Aritinercept contains an IgG4 Fc domain with no appreciable effector function (others use IgG1 Fc domain)

IgG4 is considered the least inflammatory across the IgG subclasses, in part because it poorly activates the complement system b

BAFF APRIL

Aritinercept

® a Mathur et al., J Clin Med 2023

b Oskam et al., Front Immun 2023

BAFF=B cell-activating factor; APRIL=a proliferation-inducing ligand;

BCMA=B cell maturation antigen; TACI=transmembrane activator and 18

CAML interactor; Fc=fragment crystallizable; IgG4=immunoglobulin G4

Role of BAFF and APRIL

BAFF and APRIL are important cytokines that regulate B cell survival and differentiation, whose targets are expressed on B cells at different stages of B cell development a

Targeting both BAFF and APRIL depletes a broader set of B cells, including plasma cells, than targeting a single cytokine

Aritinercept may prevent the activation of autoreactive B cells and reduce their numbers and associated immunoglobulins (antibodies) in the body, thereby reducing important drivers of B cell-mediated autoimmune diseases

APRIL Dependency

BAFF Dependency

® a Mathur et al., J Clin Med 2023 19

b Schrezenmeier et al., J Am Soc Nephrol 2018

Aritinercept Is a High Affinity Dual BAFF/APRIL Inhibitor a

Drug (Sponsor)

BAFF

APRIL

Kd (pM)

Compared to Aritinercept

Kd (pM)

Compared to Aritinercept

Aritinercept (Aurinia)

147

N/A

Atacicept (Vera)

856

5.8x

1.9x

Telitacicept (RemeGen/Vor Bio)

609

4.1x

2.6x

Aritinercept has high binding affinity for both BAFF and APRIL as compared to other dual BAFF/APRIL inhibitors

® a Data on file 20

Disclaimer

Aurinia Pharmaceuticals Inc. published this content on May 07, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 07, 2026 at 12:36 UTC.